Skip to main content

Fundamentals-first equity research for GCC markets

Screener Disclosures Contact Us Privacy Policy Terms of Use

© 2026 premargin. All rights reserved.

LinkedIn X Instagram

Research updates, no noise

you@example.com Research updates, no noise

you@example.com

Qatar Index10,021.90-1.4%

DFM Index5,510.99-0.1%

TASI11,078.89-0.1%

Emirates NBD27.60-3.2%

Dubai Electricity & Water Authority2.65+0.4%

EMAAR12.10-0.4%

EMAARDEV13.750.0%

ADNOC GAS3.240.0%

First Abu Dhabi Bank17.38-1.0%

Emirates Telecom18.78+0.6%

Abu Dhabi Commercial Bank12.64+0.8%

ALRAJHI104.10-0.2%

MAADEN63.70-1.2%

SABIC58.40-0.9%

Boubyan Bank0.68-0.6%

GULF BANK0.33+0.6%

Commercial Bank Of Kuwait0.47-3.3%

Burgan Bank0.210.0%

Industries Qatar10.66-1.8%

Qatar Islamic Bank22.32-1.2%

Ooredoo12.19-3.5%

Qatar Index10,021.90-1.4%

DFM Index5,510.99-0.1%

TASI11,078.89-0.1%

Emirates NBD27.60-3.2%

Dubai Electricity & Water Authority2.65+0.4%

-0.4%

EMAARDEV13.750.0%

ADNOC GAS3.240.0%

First Abu Dhabi Bank17.38-1.0%

Emirates Telecom18.78+0.6%

Abu Dhabi Commercial Bank12.64+0.8%

ALRAJHI104.10-0.2%

MAADEN63.70-1.2%

SABIC58.40-0.9%

Boubyan Bank0.68-0.6%

GULF BANK0.33+0.6%

Commercial Bank Of Kuwait0.47-3.3%

Burgan Bank0.210.0%

Industries Qatar10.66-1.8%

Qatar Islamic Bank22.32-1.2%

Ooredoo12.19-3.5%

Resume trading on Gulf Pharmaceutical Industries-JULPHAR shares on 27 Mar 2026 | premargin

Resume trading on Gulf Pharmaceutical Industries-JULPHAR shares on 27 Mar 2026

·ADX·Other·March 27, 2026·View on exchange

AI Summary

Trading of Julphar shares is scheduled to resume on the Abu Dhabi Securities Exchange on March 27, 2026, following the release of the 2025 audited financial results.
The company reported a total net profit of AED 173.3 million for the full year 2025, with net sales from continuing operations increasing 8.4% to AED 1,075.5 million.

Julphar accepted a binding offer from Al Batha Healthcare Group L.L.C. to divest its retail and distribution operations in the UAE and Oman, which are now classified as assets held for sale.

The Board of Directors did not recommend a dividend for 2025 due to accumulated losses, despite a 71.1% year-on-year reduction in net debt to AED 263.8 million.

Loading PDF preview...

Attachments

Resume trading on Gulf Pharmaceutical Industries-JULPHAR shares on 27 Mar 2026

Gulf Pharmaceutical Industries

Gulf Pharmaceutical Industries